Please wait while the formulary information is being retrieved.
IMBRUVICA (ibrutinib)
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Small lymphocytic lymphoma
- Chronic lymphocytic leukemia with 17p deletion
- Graft versus host disease
- Marginal zone lymphoma
- Small lymphocytic lymphoma with 17p deletion
- Waldenstrom's macroglobulinemia
140 mg tablet
- 1 tablet (140 mg) by oral route once daily at the same time eachday
280 mg tablet
- 1 tablet (280 mg) by oral route once daily at the same time eachday
420 mg tablet
- 1 tablet (420 mg) by oral route once daily at the same time eachday
560 mg tablet
- 1 tablet (560 mg) by oral route once daily at the same time eachday
140 mg capsule
- 1 capsule (140 mg) by oral route once daily at the same time each day
70 mg capsule
- 1 capsule (70 mg) by oral route once daily at the same time eachday
Chronic lymphocytic leukemia
- 1 capsule (70 mg) by oral route once daily at the same time eachday
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
Chronic lymphocytic leukemia with 17p deletion
- 1 capsule (70 mg) by oral route once daily at the same time eachday
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
Graft versus host disease
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
Mantle cell lymphoma
- 1 capsule (70 mg) by oral route once daily at the same time eachday
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
- 1 tablet (560 mg) by oral route once daily at the same time eachday
- 4 capsules (560 mg) by oral route once daily at the same time each day
- 4 tablets (560 mg) by oral route once daily at the same time each day
- 2 tablets (560 mg) by oral route once daily at the same time each day
Marginal zone lymphoma
- 1 capsule (70 mg) by oral route once daily at the same time eachday
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
- 1 tablet (560 mg) by oral route once daily at the same time eachday
- 4 capsules (560 mg) by oral route once daily at the same time each day
- 4 tablets (560 mg) by oral route once daily at the same time each day
- 2 tablets (560 mg) by oral route once daily at the same time each day
Small lymphocytic lymphoma
- 1 capsule (70 mg) by oral route once daily at the same time eachday
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
Small lymphocytic lymphoma with 17p deletion
- 1 capsule (70 mg) by oral route once daily at the same time eachday
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
Waldenstrom's macroglobulinemia
- 1 capsule (70 mg) by oral route once daily at the same time eachday
- 2 capsules (140 mg) by oral route once daily at the same time each day
- 1 capsule (140 mg) by oral route once daily at the same time each day
- 1 tablet (140 mg) by oral route once daily at the same time eachday
- 2 tablets (280 mg) by oral route once daily at the same time each day
- 2 capsules (280 mg) by oral route once daily at the same time each day
- 4 capsules (280 mg) by oral route once daily at the same time each day
- 1 tablet (280 mg) by oral route once daily at the same time eachday
- 3 capsules (420 mg) by oral route once daily at the same time each day
- 3 tablets (420 mg) by oral route once daily at the same time each day
- 1 tablet (420 mg) by oral route once daily at the same time eachday
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- Acid Reducer (cimetidine)
- Acid Relief (cimetidine)
- aprepitant
- atazanavir
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Belladonna-phenobarbital
- Calan
- Calan Sr
- calcium-mag-B complex-D3-hrb61
- carbamazepine
- Carbatrol
- Cardizem
- Cardizem Cd
- Cardizem La
- Cartia Xt
- Cerebyx
- cimetidine
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- clozapine
- Clozaril
- Cold & Flu Fighter
- crizotinib
- cyclosporine
- cyclosporine modified
- darunavir
- deferiprone
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Diflucan
- Dilacor Xr
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Dilt-xr
- diltiazem HCl
- Donnatal
- dronedarone
- Emend
- enzalutamide
- Epitol
- Equetro
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- Fatigue Relief Complex
- Fazaclo
- Ferriprox
- fluconazole
- fluconazole in dextrose(iso-o)
- fluconazole in NaCl (iso-osm)
- fosamprenavir
- fosaprepitant
- fosphenytoin
- Gengraf
- Gleevec
- Heartburn Relief
- imatinib
- isoniazid-rifamp-pyrazinamide
- Juxtapid
- Lexiva
- lomitapide
- Luminal
- Matzim La
- Multaq
- Mycobutin
- Mysoline
- Neoral
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Prezista
- primidone
- Reyataz
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- Sandimmune
- St. John's wort
- Tagamet Hb
- Tarka
- Taztia Xt
- Tegretol
- Tegretol Xr
- Tiazac
- trandolapril-verapamil
- verapamil
- Verelan
- Verelan Pm
- Versacloz
- vit C-St. John wort-elder-hb30
- Women's Complex
- Xalkori
- Xtandi
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Anemia
- Disease of liver
- Hemorrhage
- Increased risk of bleeding
- Neutropenic disorder
- Pregnancy
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- Atrial fibrillation
- Atrial flutter
- Hypertension
- Invasive surgical procedure
- Ventricular tachycardia
IMBRUVICA (ibrutinib)
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Small lymphocytic lymphoma
- Chronic lymphocytic leukemia with 17p deletion
- Graft versus host disease
- Marginal zone lymphoma
- Small lymphocytic lymphoma with 17p deletion
- Waldenstrom's macroglobulinemia
- Anemia
- Hemorrhage
- Infection
- Neutropenic disorder
- Pneumonia
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Bruising
- Constipation
- Diarrhea
- Dyspnea
- Fatigue
- Fever
- Musculoskeletal pain
- Nausea
- Peripheral edema
- Skin rash
- Upper respiratory infection
- Vomiting
More Frequent
Severe
Less Severe
- Atrial fibrillation
- Atrial flutter
- Gastrointestinal hemorrhage
- Hypertension
- Arthralgias
- Blurred vision
- Cough
- Dehydration
- Dizziness
- Dyspepsia
- Ecchymosis
- Epistaxis
- General weakness
- Headache disorder
- Hematuria
- Insomnia
- Muscle spasm
- Petechiae
- Reduced visual acuity
- Sinusitis
- Skin and skin structure infection
- Stomatitis
- Symptoms of anxiety
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Chemotherapy-induced hyperuricemia
- Hepatic cirrhosis
- Hepatic failure
- Interstitial lung disease
- Intracranial bleeding
- Panniculitis
- Pneumocystis jirovecii pneumonia
- Progressive multifocal leukoencephalopathy
- Reactivation of hepatitis B
- Renal failure
- Squamous cell carcinoma of skin
- Stevens-johnson syndrome
- Subdural intracranial hemorrhage
- Ventricular arrhythmias
Less Severe
- Basal cell carcinoma of skin
- Onycholysis
- Peripheral neuropathy
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ibrutinib
No safety and efficacy established.
- 1 Day – 18 Years
- No safety and efficacy established.
Ibrutinib
- Severity Level:
D
- Additional Notes: Insufficient human data; teratogenic in animals
Contraindicated
Ibrutinib
Insufficient human data available; potential for serious adverse effects
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data available; potential for serious adverse effects |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Ibrutinib
Cardiovascular-Increased risk of atrial fibrillation and hypertension in elderly patients. General-Infection (pneumonia), anemia, thrombocytopenia, diarrhea and dehydration occurred more commonly in the elderly in clinical trials.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Chronic lymphocytic leukemia | |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| Chronic lymphocytic leukemia with 17p deletion | |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| Graft versus host disease | |
| D89.81 | Graft-versus-host disease |
| D89.810 | Acute graft-versus-host disease |
| D89.811 | Chronic graft-versus-host disease |
| D89.812 | Acute on chronic graft-versus-host disease |
| D89.813 | Graft-versus-host disease, unspecified |
| Mantle cell lymphoma | |
| C83.1 | Mantle cell lymphoma |
| C83.10 | Mantle cell lymphoma, unspecified site |
| C83.11 | Mantle cell lymphoma, lymph nodes of head, face, and neck |
| C83.12 | Mantle cell lymphoma, intrathoracic lymph nodes |
| C83.13 | Mantle cell lymphoma, intra-abdominal lymph nodes |
| C83.14 | Mantle cell lymphoma, lymph nodes of axilla and upper limb |
| C83.15 | Mantle cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.16 | Mantle cell lymphoma, intrapelvic lymph nodes |
| C83.17 | Mantle cell lymphoma, spleen |
| C83.18 | Mantle cell lymphoma, lymph nodes of multiple sites |
| C83.19 | Mantle cell lymphoma, extranodal and solid organ sites |
| Marginal zone lymphoma | |
| C83.0 | Small cell b-cell lymphoma |
| C83.00 | Small cell b-cell lymphoma, unspecified site |
| C83.01 | Small cell b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.02 | Small cell b-cell lymphoma, intrathoracic lymph nodes |
| C83.03 | Small cell b-cell lymphoma, intra-abdominal lymph nodes |
| C83.04 | Small cell b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.05 | Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.06 | Small cell b-cell lymphoma, intrapelvic lymph nodes |
| C83.07 | Small cell b-cell lymphoma, spleen |
| C83.08 | Small cell b-cell lymphoma, lymph nodes of multiple sites |
| C83.09 | Small cell b-cell lymphoma, extranodal and solid organ sites |
| Small lymphocytic lymphoma | |
| C83.0 | Small cell b-cell lymphoma |
| C83.00 | Small cell b-cell lymphoma, unspecified site |
| C83.01 | Small cell b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.02 | Small cell b-cell lymphoma, intrathoracic lymph nodes |
| C83.03 | Small cell b-cell lymphoma, intra-abdominal lymph nodes |
| C83.04 | Small cell b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.05 | Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.06 | Small cell b-cell lymphoma, intrapelvic lymph nodes |
| C83.07 | Small cell b-cell lymphoma, spleen |
| C83.08 | Small cell b-cell lymphoma, lymph nodes of multiple sites |
| C83.09 | Small cell b-cell lymphoma, extranodal and solid organ sites |
| Small lymphocytic lymphoma with 17p deletion | |
| C83.00 | Small cell b-cell lymphoma, unspecified site |
| C83.01 | Small cell b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.02 | Small cell b-cell lymphoma, intrathoracic lymph nodes |
| C83.03 | Small cell b-cell lymphoma, intra-abdominal lymph nodes |
| C83.04 | Small cell b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.05 | Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.06 | Small cell b-cell lymphoma, intrapelvic lymph nodes |
| C83.07 | Small cell b-cell lymphoma, spleen |
| C83.08 | Small cell b-cell lymphoma, lymph nodes of multiple sites |
| C83.09 | Small cell b-cell lymphoma, extranodal and solid organ sites |
| Waldenstrom's macroglobulinemia | |
| C88.0 | Waldenstrom macroglobulinemia |
| 0-9 | A-Z |
|---|---|
| C83.0 | Small cell b-cell lymphoma |
| C83.0 | Small cell b-cell lymphoma |
| C83.00 | Small cell b-cell lymphoma, unspecified site |
| C83.00 | Small cell b-cell lymphoma, unspecified site |
| C83.00 | Small cell b-cell lymphoma, unspecified site |
| C83.01 | Small cell b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.01 | Small cell b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.01 | Small cell b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.02 | Small cell b-cell lymphoma, intrathoracic lymph nodes |
| C83.02 | Small cell b-cell lymphoma, intrathoracic lymph nodes |
| C83.02 | Small cell b-cell lymphoma, intrathoracic lymph nodes |
| C83.03 | Small cell b-cell lymphoma, intra-abdominal lymph nodes |
| C83.03 | Small cell b-cell lymphoma, intra-abdominal lymph nodes |
| C83.03 | Small cell b-cell lymphoma, intra-abdominal lymph nodes |
| C83.04 | Small cell b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.04 | Small cell b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.04 | Small cell b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.05 | Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.05 | Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.05 | Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.06 | Small cell b-cell lymphoma, intrapelvic lymph nodes |
| C83.06 | Small cell b-cell lymphoma, intrapelvic lymph nodes |
| C83.06 | Small cell b-cell lymphoma, intrapelvic lymph nodes |
| C83.07 | Small cell b-cell lymphoma, spleen |
| C83.07 | Small cell b-cell lymphoma, spleen |
| C83.07 | Small cell b-cell lymphoma, spleen |
| C83.08 | Small cell b-cell lymphoma, lymph nodes of multiple sites |
| C83.08 | Small cell b-cell lymphoma, lymph nodes of multiple sites |
| C83.08 | Small cell b-cell lymphoma, lymph nodes of multiple sites |
| C83.09 | Small cell b-cell lymphoma, extranodal and solid organ sites |
| C83.09 | Small cell b-cell lymphoma, extranodal and solid organ sites |
| C83.09 | Small cell b-cell lymphoma, extranodal and solid organ sites |
| C83.1 | Mantle cell lymphoma |
| C83.10 | Mantle cell lymphoma, unspecified site |
| C83.11 | Mantle cell lymphoma, lymph nodes of head, face, and neck |
| C83.12 | Mantle cell lymphoma, intrathoracic lymph nodes |
| C83.13 | Mantle cell lymphoma, intra-abdominal lymph nodes |
| C83.14 | Mantle cell lymphoma, lymph nodes of axilla and upper limb |
| C83.15 | Mantle cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.16 | Mantle cell lymphoma, intrapelvic lymph nodes |
| C83.17 | Mantle cell lymphoma, spleen |
| C83.18 | Mantle cell lymphoma, lymph nodes of multiple sites |
| C83.19 | Mantle cell lymphoma, extranodal and solid organ sites |
| C88.0 | Waldenstrom macroglobulinemia |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| D89.81 | Graft-versus-host disease |
| D89.810 | Acute graft-versus-host disease |
| D89.811 | Chronic graft-versus-host disease |
| D89.812 | Acute on chronic graft-versus-host disease |
| D89.813 | Graft-versus-host disease, unspecified |
Formulary Reference Tool